Louis Reichardt

Director
SFARI

Louis Reichardt joined the foundation to lead SFARI in 2013. Prior to assuming this post, he was the Jack D. and DeLoris Lange endowed chair in cell physiology at the University of California, San Francisco, where he had directed its renowned neuroscience graduate program since 1988. A Fulbright scholar with an undergraduate degree from Harvard University and a Ph.D. from Stanford University, Reichardt was a research fellow at Harvard Medical School and a Howard Hughes investigator for more than 20 years.

The recipient of a Guggenheim fellowship in 1985, he is a fellow of both the American Association for the Advancement of Science and the American Academy of Arts and Sciences. He was one of three founding editors of the journal Neuron and is a senior editor of the Journal of Cell Biology. He serves on the editorial boards of several other journals as well as the scientific advisory boards of the Christopher and Dana Reeve Spinal Cord Injury and Paralysis Foundation and the Myelin Repair Foundation.

Reichardt’s research has focused on neurotrophins, a family of proteins that play a key role in neuron functioning, and on another family of proteins that promote the adhesion of nerve cells to each other. He has made major contributions to the study of intracellular signaling pathways that mediate the effects of these proteins ‰ÛÓ including the Wnt pathway, which may play a role in autism spectrum disorders.

From this contributor

Explore more from The Transmitter

Two lab mice fighting.

From friend to foe: How the brain updates feelings toward others

A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.

By Natalia Mesa
9 July 2026 | 5 min read
Illustration of scientist in lab coat looking at shelves of computer network models.

Mass-produced science is coming. What happens to scientists?

Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.

By Kenneth Harris
9 July 2026 | 9 min read
Adriano Aguzzi.

Neuropathologist not guilty of research misconduct, says university probe

The investigation determined that seven papers by corresponding author Adriano Aguzzi have “scientifically significant” errors, which Aguzzi attributes to his former students.

By Dalmeet Singh Chawla
8 July 2026 | 5 min read